28th National Hepatitis Symposium

Join us for a series of 5 state of the art, free webinars from August to November 2021. These exciting and informative webinars will provide updates on the current perspectives, diagnosis and management, as well as the latest advances in treatment.

   Event Details
Date
5 webinars from August to November 2021
Location
Online

About this event

The webinar series will include sessions on hepatitis B, and hepatitis C and other important liver diseases, including advanced hepatocellular carcinoma, portal hypertension, metabolic associated fatty liver disease and hepatitis D.

The webinars will provide lectures, interactive cases and panel based discussions for general gastroenterologists, ID physicians, nurses, scientists and community advocates with state of the art knowledge.

Location Details

This series of webinars will be held online. A link to join the event will be emailed to attendees before the event begins.

Dates and Times

Sessions will take place online between 6 and 7:30pm over 5 dates from August to November.

Webinar details

Webinar 1

Non-curative HCC: Beyond Systemic Therapy


Tuesday 10th August


Agenda
6.00pm - 6:05pm

Welcome & introduction (Dr Jessica Howell)

6.05pm - 6:20pm

Preparing patients for immunotherapy & managing complications: the oncologist’s perspective (Dr Rohini Sharma)

6.20pm - 6:35pm

Preparing patients for immunotherapy & managing complications: the gastroenterologist’s perspective (A/Prof Simone Strasser)

6.35pm - 6:45pm

Liver supportive care models in CLD and HCC (Prof Jennifer Phillip)

6.45pm - 7:00pm

Q+A

7.00pm - 7:30pm

Case based panel discussion


Speakers

Dr Jessica Howell (Chair)

Gastroenterologist and Hepatologist, St Vincent’s Hospital Melbourne
CR Roper Senior Research Fellow, University of Melbourne
Senior Research Fellow, Burnet Institute
Adjunct Senior Research Fellow, Monash University

Dr Rohini Sharma

Lead of Liver Cancer and Neuroendocrine Cancers, Imperial College, London

A/Prof Simone Strasser

Senior Specialist of AW Morrow Gastroenterology and Liver Centre, Royal Price Alfred Hospital, Sydney

Prof Jennifer Philip

Chair of Palliative Medicine, University of Melbourne, St Vincent’s Hospital


Details

The incidence of hepatocellular carcinoma (HCC) has been rising at an alarming rate and is the 6th most common cancer and the 2nd most common cause of cancer death in Australia. HCC carries a poor prognosis with a 5 year survival of only 15%, owing to advanced disease at presentation and suboptimal treatment options for many patients. The recently approved immunotherapy for advanced HCC has changed the treatment landscape of HCC.

This webinar will discuss the use of immunotherapy for HCC with a focus on patient preparation and management of toxicities from the hepatologist and oncologist point of view. In addition, this webinar will discuss liver supportive care models for individuals with end stage liver disease and advanced HCC.

Webinar 2

Portal Hypertension and End-Stage Liver Disease


Tuesday 24th August


Agenda
6.00pm - 6:05pm

Welcome & introduction (A/Prof Jacinta Holmes)

6.05pm - 6:15pm

Changing indications for TIPS (Prof Golo Ahlenstiel)

6.15pm - 6:25pm

Management of patients with refractory ascites (Dr Siddarth Sood)

6.25pm - 6:35pm

Hepatorenal syndrome – what’s new? (Dr Marie Sinclair)

6.35pm - 6:45pm

Q & A

6.45pm - 7:30pm

Case based panel discussion


Speakers

A/Prof Jacinta Holmes (Chair)

Gastroenterologist and Hepatologist, St Vincent’s Hospital Melbourne
Clinical Associate Professor, University of Melbourne

Prof Golo Ahlenstiel

Chair of Medicine, Blacktown Hospital
Lead of Liver Immunology, Westmead Institute for Medical Research

Dr Siddharth Sood

Senior Staff Specialist and Head of Hepatology, Royal Melbourne Hospital

Dr Marie Sinclair

Gastroenterologist and Hepatologist, Austin Health


Details

Portal hypertension is a complication of cirrhosis that is the main predictor of morbidity and mortality. Over the last decade, and in particular the last 5 years, there has been a paradigm shift in the management of portal HTN to prevent decompensation events and to try to prevent disease progression.

This webinar will cover the changing indications for TIPS, management of refractory ascites and what’s new in hepatorenal syndrome.

Webinar 3

MAFLD - The Growing Hepatitis Epidemic


Tuesday 7th September


Agenda
6.00pm - 6:05pm

Welcome & introduction (A/Prof Marno Ryan)

6.05pm - 6:15pm

MAFLD 101 for the GP: Diagnosis and assessment of liver disease (Dr Ann Farrell)

6.15pm - 6:25pm

Triage of patients: who to refer, algorithms to stratify patients needing referral (Prof Elizabeth Powell)

6.25pm - 6:40pm

Management of obesity in the age of GLP-1s (Dr Priya Sumithran)

6.40pm - 6:50pm

Q & A

6.50pm - 7:30pm

Case based panel discussion


Speakers

A/Prof Marno Ryan (Chair)

Gastroenterologist and Hepatologist, St Vincent’s Hospital, Melbourne
Associate Professor of Medicine at the University of Melbourne

Dr Ann Farrell

Gastroenterologist and Hepatologist, St Vincent’s Hospital Melbourne

Prof Elizabeth Powell

Director of Clinical training and Hepatologist, Princess Alexandra Hospital, Brisbane

Dr Priya Sumithran

Head, Obesity Medicine, Austin Health
Group Leader, Obesity Research Group, University of Melbourne
Endocrinologist, St Vincent’s Hospital Melbourne


Details

Fatty liver disease is the most common cause of liver disease globally, and is expected to be the leading indication for liver transplantation over the next decade. Identifying which patients have inflammation and fibrosis, and those at risk for disease progression is a key step in the management of these patients.

Management requires a multidisciplinary approach, and tailoring of therapeutic options to the patient. The development of the GLP-1 agonists has been an exciting addition to the fatty liver treatment armamentarium.

This webinar will discuss the diagnosis and management of fatty liver disease, triaging of patient sin primary care and algorithms to stratify patients requiring specialist referral and obesity in the age of GLP-1s.

Webinar 4

HBV & HDV - Changing Landscapes


Tuesday 12th October


Agenda
6.00pm - 6:05pm

Welcome & introduction (A/Prof Jacinta Holmes)

6.05pm - 6:20pm

Management of HBV 101: the basics and treatment (including current Rx and goals of treatment, brief discussion of new treatments) & HCC screening: who, how and when (Dr Jessica Howell)

6.20pm - 6:30pm

HBV: is cure possible? (A/Prof Jacinta Holmes)

6.30pm - 6:40pm

HDV: the forgotten hepatitis (Prof Heiner Wedemeyer)

6.40pm - 6:50pm

Q & A

6.50pm - 7:30pm

Case based panel discussion


Speakers

A/Prof Jacinta Holmes (Chair)

Gastroenterologist and Hepatologist, St Vincent’s Hospital Melbourne
Clinical Associate Professor, University of Melbourne

Dr Jessica Howell

Gastroenterologist and Hepatologist, St Vincent’s Hospital Melbourne
CR Roper Senior Research Fellow, University of Melbourne
Senior Research Fellow, Burnet Institute
Adjunct Senior Research Fellow, Monash University

Prof Heiner Wedemeyer

Professor and Chairman of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany


Details

Hepatitis B remains a significant contributor to liver disease, liver-related death and liver cancer worldwide. Hepatitis B is not curable with current therapies, but can be suppressed with nucleos(t)ide analogues.

In order to meet the World Health Organisation targets of a 90% reduction in new infections and a 65% reduction in deaths from hepatitis B, vaccination strategies and novel treatments strategies that better target and even cure hepatitis B are required.

Hepatitis B remains a leading cause of liver cancer globally, and patients at high risk for liver cancer should be enrolled in a screening program for early detection.

Hepatitis D infection can only occur in the setting of Hepatitis B infection, and is associated with more accelerated liver injury, leading to cirrhosis at a much earlier age. Previously, the only treatment effective for Hepatitis D was Pegylated-interferon, which not only had to be administered for prolonged durations, but was also contraindicated in many patients. Recently, bulevirtide when combined with Pegylated-interferon has been shown to be superior to Pegylated-interferon alone for the treatment of Hepatitis B/Hepatitis D coinfection, and will be in available in Australia in the next 12 months.

This webinar aims to provide you with knowledge about hepatitis B to increase awareness and confidence around hepatitis B monitoring and screening in the community, liver cancer screening guidelines for patients with hepatitis B, and about hepatitis D, the forgotten hepatitis. We hope this webinar will assist in engaging and managing individuals in hepatitis B care.

Webinar 5

HCV Elimination - Are we there yet?


Tuesday 9th November


Agenda
6.00pm - 6:05pm

Welcome & introduction (Prof Jacinta Holmes)

6.05pm - 6:15pm

Management of HCV 101: the basics (Prof Jacinta Holmes)

6.15pm - 6:30pm

HCV elimination: how are we doing? (Prof Ed Gane)

6.30pm - 6:40pm

New models of care: point-of-care testing and care navigation (Dr Michael MacIsaac & Dr Tim Papaluca)

6.40pm - 6:50pm

Q & A

6.50pm - 7:30pm

Case based panel discussion


Speakers

A/Prof Jacinta Holmes (Chair)

Gastroenterologist and Hepatologist, St Vincent’s Hospital Melbourne
Clinical Associate Professor, University of Melbourne

Prof Ed Gane

Professor of Medicine, University of Auckland
Deputy Director of the Liver Unit, Auckland City Hospital

Dr Michael MacIsaac

Hepatology PhD Fellow, St Vincent’s Hospital, University of Melbourne

Dr Tim Papaluca

Gastroenterologist and Hepatology Fellow, Royal Free Hospital, London


Details

Hepatitis C remains a global health challenge, but is easily curable with the new DAAs, with cure rates over 95% in all individuals. The World Health Organisation has set ambitious targets to eliminate hepatitis C with an 80% reduction in new infections and a 65% reduction in deaths from hepatitis C. In order to achieve these targets, we need to better identify and diagnose patients living with hepatitis C, and offer treatment to all individuals with hepatitis C.

This webinar aims to provide you with the knowledge and confidence to increase awareness of Hepatitis C and to encourage individuals to engage with the Hepatitis C testing and treatment within the community. This webinar will also explore some exciting new models of care and international models that have been effective in engaging individuals in hepatitis C care.

This event is supported by

Platinum

Silver

Bronze

Webinars presented by: